Press releases

22 March, 2018

Regulatory

NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 22 March 2018, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company"). A summary of the resolutions follows. All resolutions were passed ...

29 January, 2018

Regulatory

NeuroVive reports breakthrough in mitochondrial myopathy project

Lund, Sweden, 29 January 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a breakthrough in the company's project NVP025 for developing treatment of mitochondria ...

13 December, 2017

Regulatory

NeuroVive’s KL1333 program granted orphan drug designation by the European Commission

Lund, Sweden, 13 December 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), announced today that the European Commission has granted orphan drug designation (ODD) for the compa ...

11 December, 2017

Regulatory

NeuroVive reports promising progress in its clinical project for genetic mitochondrial diseases, KL1333

Lund, Sweden, 11 December 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies' join ...

30 November, 2017

Regulatory

NeuroVive’s genetic mitochondrial disease program NVP015 reaches significant milestone

Lund, Sweden, 30 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that molecules in its NVP015 program have demons ...

8 November, 2017

Regulatory

NeuroVive’s Clinical Development Project KL1333 Receives Positive Opinion on European Orphan Drug Designation

Lund, Sweden, 8 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the Committee for Orphan Medicinal Products ...

31 October, 2017

Regulatory

NeuroVive signs collaboration agreement with University of Florida for TBI biomarker development

Lund, Sweden, 31 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has signed a collaboration agreement with Kevin K.W. Wang, Ph.D., of ...

18 October, 2017

NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research

Lund, Sweden, 18 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive and Ramin Massoumi at Lund Univers ...

5 October, 2017

NeuroVive’s collaborator the Children’s Hospital of Philadelphia awarded NIH grant to study NVP015 against chemical threats

Lund, Sweden, 5 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF, the mitochondrial medicine company, today announced that its research collaboration partner the Childre ...

3 October, 2017

NeuroVive presents innovative metabolic regulators for NASH. Abstract selected as top tier at The Liver Meeting 2017

Lund, Sweden, 3 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with new preclinical data related ...

21 September, 2017

Regulatory

NeuroVive receives positive EMA Scientific Advice on its NeuroSTAT development plan for TBI

Lund, Sweden, 21 September 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced positive feedback on its requested Scientific A ...

27 June, 2017

Regulatory

NeuroVive and Yungjin Pharm start clinical development in genetic mitochondrial disease

Lund, Sweden and Seoul, South Korea, 27 June 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today ann ...